OCUPHIRE PHARMA INC (OCUP) Stock News
NASDAQ:OCUP - Nasdaq - US67577R1023 - Common Stock - Currency: USD
OCUP Latest News, Press Relases and Analysis
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
/PRNewswire/ -- The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus...
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
Ocuphire Pharma acquires Opus Genetics, expanding its IRD gene therapy pipeline. The renamed company, Opus Genetics, will trade under "IRD" by late October 2024.
Ocuphire Pharma Announces Acquisition of Opus Genetics
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New...
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile...
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocuphire Pharma (NASDAQ:OCUP) just reported results for the second quarter of 2...
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocuphire Pharma (NASDAQ:OCUP) just reported results for the first quarter of 20...
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity...
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q2 2024
OCUP stock results show that Ocuphire Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
VEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025 LYNX-2 Phase 3 Study...
Ocuphire Pharma to Present at Two Investor Conferences in August
FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the...
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocuphire Pharma (NASDAQ:OCUP) just reported results for the fourth quarter of 2...
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company...
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024
OCUP stock results show that Ocuphire Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Pharma to Present at the Aegis Virtual Conference
FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on...
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire’s Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 ...
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on...
OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023
OCUP stock results show that Ocuphire Pharma missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on...
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic...
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Pharma appointed Nirav Jhaveri as CFO (NASDAQ:OCUP)
Ocuphire Pharma strengthens leadership team with the appointment of Nirav Jhaveri as CFO and Ash Jayagopal as Chief Scientific and Development Officer.
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer ...
3 Value Stocks to Buy on the Dip: February 2024
While many investors continue to chase after the latest trends, these underappreciated value stocks to buy could be the true winners.
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
FARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire Pharma files for a $175M mixed securities shelf (NASDAQ:OCUP)
Ocuphire Pharma (OCUP) files prospectus for a mixed shelf offering, aiming to raise up to $175M; not an offer to sell securities.
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024...
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023...
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside.
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Ocuphire announces appointment of Joseph Schachle as chief operating officer (NASDAQ:OCUP)
Ocuphire Pharma appoints Joseph Schachle as chief operating officer, signaling strategic expansion for the advancement of their lead retina asset.
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate and Commercial...